|Bid||22.86 x 2200|
|Ask||23.50 x 1300|
|Day's range||22.98 - 23.50|
|52-week range||18.28 - 31.00|
|Beta (3Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||7 Aug. 2019 - 12 Aug. 2019|
|Forward dividend & yield||N/A (N/A)|
|1y target est||35.50|
Celcuity, Inc. (CELC) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Passive investing in index funds can generate returns that roughly match the overall market...
Nabriva Therapeutics (NBRV) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
The big shareholder groups in Celcuity Inc. (NASDAQ:CELC) have power over the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions Read More...
NEW YORK, Dec. 11, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced the appointment of Maureen T. Cronin, Ph.D., as the Company’s Chief Scientific Officer and Senior Vice President as of November 16, 2018. Dr. Cronin is a veteran biotechnology, translational science and diagnostic executive. “HTG is incredibly honored to have Maureen join our company as she brings extensive experience in developing high-value precision diagnostics,” said TJ Johnson, Chief Executive Officer of HTG.